Products for Research Use Only

Quisinostat

CAT: 0013-GTR19160927-01Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19160927-01Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Quisinostat (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2. (In Vitro) :Quisinostat inhibits HDAC isozymes in vitro.Quisinostat (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.Quisinostat has a broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis. (In Vivo) :Quisinostat (40 mg/kg; p.o.; once daily; for 3 days) acts as a potent HDAC1 inhibitor p21waf1, cip1 ZsGreen tumors in vivo.Quisinostat induces continuous H3 acetylation in tumor tissue in vivo.Quisinostat (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts.
CAS Number
875320-29-9
Product Name Alternative
(JNJ-26481585)
Purity
>98% (HPLC)
Solubility
DMSO:79 mg/mL (200.26 mM) ; Ethanol:<1 mg/mL (<1 mM) ; Water:<1 mg/mL (<1 mM)
Smiles
O=C (C1=CN=C (N2CCC (CNCC3=CN (C) C4=C3C=CC=C4) CC2) N=C1) NO
Molecular Formula
C21H26N6O2
Molecular Weight
394.476
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
N-hydroxy-2- (4- ((((1-methyl-1H-indol-3-yl) methyl) amino) methyl) piperidin-1-yl) pyrimidine-5-carboxamide